Scarica l'app Stockscreener
1,180.16
2.39%
-28.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Lilly Eli Co Borsa (LLY) Ultime notizie
LLY Looks 21.9% Undervalued on GF Value™ - GuruFocus
Oppenheimer Asset Management Inc. Has $95.32 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Purchased by SWS Partners - MarketBeat
Boone County residents denied hearing on possible Eli Lilly pollutants - Pharos-Tribune
Elyxium Wealth LLC Has $7.30 Million Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly (LLY) Raises 2026 Revenue Guidance, Is The Stock Still A Bargain? - simplywall.st
Eli Lilly (NYSE:LLY) stock in focus as obesity treatment demand lifts guidance - Kalkine Media
Eli Lilly’s Weight-Loss Pill Just Went Global. Is LLY Stock Too Late to Buy? - TIKR.com
Mill Capital Management LLC Boosts Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Jennison Associates LLC Increases Position in Eli Lilly and Company $LLY - MarketBeat
Fire Capital Management LLC Has $2.54 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
This Week’s Top 5: Eli Lilly's GLP-1, Novo Nordisk and P&G - Healthcare Digital
PRIMECAP Management Co trims Eli Lilly stake by 50K - TipRanks
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) - fool.com
Eli Lilly and Company (NYSE:LLY) Trading Down 2.2%What's Next? - MarketBeat
Veeva Systems (VEEV) Could Be 24% Undervalued On Eli Lilly Global Vault CRM Rollout - simplywall.st
LLY Looks 21.8% Undervalued on GF Value™ - GuruFocus
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Eli Lilly sues companies that allegedly sold unapproved versions of new GLP-1 - BenefitsPRO
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug - The American Journal of Managed Care® (AJMC®)
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger - Yahoo Finance
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger - The Motley Fool
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - Moomoo
Berenberg Bank Initiates Eli Lilly and Co(LLY.US) With Hold Rating, Announces Target Price $1,220 - Moomoo
Kirkland & Ellis Helps Eli Lilly Sue to Shut Down Alleged Black Market for GLP 1 - Law.com
Lilly Claims 6 Vendors Illegally Sold Obesity Drug Candidate - Law360
Eli Lilly and Company (NYSE:LLY) Stays Tied To The Metabolic Health Story - kalkinemedia.com
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race - ca.finance.yahoo.com
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity - AOL.com
Eli Lilly targets booming black market for retatrutide - STAT
Novo CEO says obesity market won't be winner-take-all battle with Lilly - Reuters
Eli Lilly Stock (LLY) Opinions on Q2 Earnings Results - Quiver Quantitative
Eli Lilly Shares Approach Record High While Retatrutide Legal Action Secures New Obesity Hope - TechStock²
Lilly veteran named director of IU Kelley School’s life sciences center - ibj.com
Lilly Filed Six Lawsuits Against 14,000 Listings. The Real Target Is the Payment Layer - Business Model Analyst
Lilly gains access to market that could add millions of customers - thestreet.com
Eli Lilly is a great company. Is it still a great stock? - Investing.com
Eli Lilly is a great company. Is it still a great stock? By Investing.com - Investing.com Canada
Eli Lilly cracks down on illicit weight loss drug trade with US lawsuits - Pharmaceutical Technology
Lilly Takes On Peptide Industry to Protect Buzzy Obesity Shot Retatrutide - Bloomberg.com
Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Gains as Stock Slumps - finance.yahoo.com
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide - Reuters
Eli Lilly Sues Six Companies Over Unauthorized Retatrutide Sales - RTTNews
Is Eli Lilly (NYSE:LLY) Drawing Fresh Attention As Incretin Therapies Advance? - Kalkine Media
Top Large Cap Pharma Stock: Jefferies Highlights Eli Lilly By Investing.com - Investing.com India
Top Large Cap Pharma Stock: Jefferies Highlights Eli Lilly - Investing.com
Understanding Attorney General v. Eli Lilly & Co.: What Regulated Businesses Should Know About Potentially Expanded MCPA Exposure - JD Supra
Eli Lilly Sues Six Firms Over Black-Market Sales of Unapproved Weight-Loss Drug - finance.biggo.com
What Is Keeping Eli Lilly (NYSE:LLY) in View as Inflation Data Nears? - Kalkine Media
‘Entirely Unverified Retatrutide’ Being Sold on Black Market: Lilly Sues 6 US Companies - Health and Me
Eli Lilly Stock Falls While Retatrutide Lawsuits Expand - TradingView
Lilly Targets Black-Market Retatrutide Sellers - TradingView
Eli Lilly sues six companies for selling illegal versions of groundbreaking weight-loss drug - Straight Arrow
Veeva Systems (VEEV) Expands AI CRM Role With Eli Lilly Win Is Its Moat Deepening? - simplywall.st
Eli Lilly files first lawsuits over retatrutide ‘black market’ - Endpoints News
Lilly escalates fight over weight-loss shots sold on black market - Indianapolis Business Journal
Eli Lilly Goes After Sellers of Its Unapproved Drug - Newser
Eli Lilly targets alleged black market sales of its experimental GLP-1 drug - The Hill
I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade) (LLY) - Seeking Alpha
Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas - Fierce Pharma
Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide - BioPharma Dive
Eli Lilly Escalates Retatrutide Fight, Reports 200-Plus Illegal Sellers to Authorities - Benzinga
Lilly escalates its fight against black market weight-loss shots - Fortune
Lilly Escalates Its Fight Against Black Market Weight-Loss Shots - Bloomberg.com
Lilly Escalates Fight Against Black Market Weight-Loss Shots (3) - Bloomberg Law News
Eli Lilly Sues 6 US Sellers Over Black-Market Retatrutide, Calls Products ‘Unverified’ - outlookbusiness.com
InduPro's 'protein neighbourhoods' draw Sanofi, Lilly backing after earlier deals - FirstWord Pharma
Lilly sues six U.S. companies for allegedly selling black-market retatrutide - PharmaLive
0.66%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):